The current financial score of Onconetix Inc is 6.17. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 17.12K, representing a year-over-year decrease of 83.92%, while its net profit experienced a year-over-year decrease of 6.16%.
The current valuation score of Onconetix Inc is 8.99. Its current P/E ratio is 0.00, which is 1680.00% below the recent high of 0.01 and 11330820.00% above the recent low of -56.65.
No earnings forecast score is currently available for Onconetix Inc. The Pharmaceuticals industry's average is 7.86.
The current price momentum score of Onconetix Inc is 7.15. Currently, the stock price is trading between the resistance level at 0.93 and the support level at 0.47, making it suitable for range-bound swing trading.
The current institutional shareholding score of Onconetix Inc is 3.00. The latest institutional shareholding proportion is 3.85%, representing a quarter-over-quarter decrease of 34.62%.
The current risk assessment score of Onconetix Inc is 1.63. The company's beta value is 2.78. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.